2024年6月,沈柏用教授在《Cell Research》【IF28.1,Q1】杂志在线发表题名为“Combination Therapy of KRAS G12V mRNA Vaccine and Pembrolizumab: Clinical Benefit in Patients with Advanced Solid Tumors.”——KRAS G12V mRNA疫苗联合...
PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis (https://pubmed.ncbi.nlm.nih.gov/39208806/) PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program(https://www...
PD-1 signaling limits expression of phospholipid phosphatase 1 and promotes intratumoral CD8+ T cell ferroptosis (https://pubmed.ncbi.nlm.nih.gov/39208806/) PD-1 combination therapy with IL-2 modifies CD8+ T cell exhaustion program(https://www.nature.com/articles/s41586-022-05257-0) IL-2R...
分析表明,自 2020 年以来,联用策略(包括一种 PDx 和至少两种其他疗法)一直在增加,占 2022 年试验的 31%。 PDx trials by type of combination therapy being tested. PDx联合靶向疗法(TT)是第二大最常见的组别,占2022年试验的23.8%,但与2021年相比下降了3.2%。与IO药物的联用占比 21.6%,去年也略有下降(-...
However, combination therapy is less well tolerated causing severe side effects. Thus, PD1 is currently tested in combination with other agents that might have an improved safety profile and induce clinical responses also in those patients that at present do not respond to anti-PD1 monotherapy....
2、Kamran Kaveh, Feng Fu, Immune checkpoint therapy modeling of PD-1/PD-L1 blockades reveals subtle difference in their response dynamics and potential synergy in combination, ImmunoInformatics, Volumes 1–2, 2021, 100004, ISSN 2667-1190, https://doi.org/10.1016/j.immuno.2021.100004.3、...
PDx trials by type of combination therapy being tested. PDx联合靶向疗法(TT)是第二大最常见的组别,占2022年试验的23.8%,但与2021年相比下降了3.2%。与IO药物的联用占比 21.6%,去年也略有下降(-1.4%)。与化疗和放疗的联用在2022年都有大幅下降(分别为-19.2%和-38.2%),PDx在单药治疗中的使用也是如此,...
PDx trials by type of combination therapy being tested. PDx联合靶向疗法(TT)是第二大最常见的组别,占2022年试验的23.8%,但与2021年相比下降了3.2%。与IO药物的联用占比 21.6%,去年也略有下降(-1.4%)。与化疗和放疗的联用在2022年都有大幅下降(分别为-19.2%和-38.2%),PDx在单药治疗中的使用也是如此,...
The combination of LIF neutralizing antibodies with the inhibition of the PD1 immune checkpoint promotes tumor regression, immunological memory and an increase in overall survival.doi:10.1038/s41467-019-10369-9Mónica Pascual-GarcíaEster Bonfill-Teixidor...
There is now an urgent need to identify mechanisms of resistance, to predict outcome and to identify targets for combination therapy. Here, with the aim of guiding future combination trials that target specific resistance mechanisms to immunotherapies, we have summarised and discussed the current ...